SERMs exhibit tissue-specific estrogen agonistic or antagonistic activity.
The SERMs include tamoxifen, raloxifene and bazedoxifene.
Tamoxifen predisposes to diabetes, lipid abnormalities and hepatic steatosis.
Raloxifene exhibits minor effects on metabolic homeostasis.
Bazedoxifene combined with conjugated estrogens prevents menopausal metabolic dysfunction in mice.